达雷妥尤单抗的临床药代动力学与药效学
达雷妥尤单抗是靶向CD38的全人源单克隆IgG1,用于多发性骨髓瘤和轻链淀粉样变性。静脉给药呈非线性药代动力学,清除率随剂量和时间下降;暴露与疗效强相关,与安全性无关。批准的16 mg/kg剂量在每周给药结束时使大多数患者靶点饱和99%。皮下制剂疗效和安全性相似,输注相关反应更低。
要点
- 达雷妥尤单抗暴露与疗效强相关,与安全性无关。
- 16 mg/kg剂量在每周给药结束时使大多数患者靶点饱和99%。
- 除骨髓瘤类型和基线白蛋白外,其他患者特征无临床相关影响。
核心结论
- 达雷妥尤单抗暴露与疗效强相关,与安全性无关。
- 批准的16 mg/kg剂量在每周给药结束时使大多数患者靶点饱和99%。
- 皮下制剂与静脉制剂疗效和安全性相似,但输注相关反应更低。
研究设计与样本
- 综述了达雷妥尤单抗的临床药代动力学和药效学特征。
主要发现
- 静脉给药后达雷妥尤单抗呈非线性药代动力学,清除率随剂量增加和时间推移而下降。
- IgG型骨髓瘤患者相比非IgG型患者达雷妥尤单抗暴露显著更低(p < 0.0001),低白蛋白患者暴露也更低。
- 无论骨髓瘤类型和自蛋白水平如何,总缓解率相似。
- 输注相关反应常见,尤其在首次输注时,需延长输注时间(约7小时)并将首剂分2天给予。
- 皮下制剂与静脉制剂暴露-反应关系相似,合并用药不影响达雷妥尤单抗药代动力学。
关键数值与推荐
- 批准的达雷妥尤单抗剂量为16 mg/kg,在每周给药结束时使大多数患者靶点饱和99%。
- 给药方案通常为每周一次持续6-9周,随后每2-4周一次。
- 目前不推荐根据疾病和患者特征调整达雷妥尤单抗剂量。
临床怎么用
- 临床使用达雷妥尤单抗时,16 mg/kg剂量无需根据肾功能、肝功能、年龄、性别、种族、体重或体能状态调整。
- 对于IgG型骨髓瘤或低白蛋白患者,虽暴露较低但总缓解率相似,无需常规剂量调整。
- 皮下制剂可替代静脉制剂以减少输注相关反应和缩短给药时间。
局限性
- 本文为综述,未报告原始研究的具体样本量、置信区间等数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab is a fully human, monoclonal immunoglobulin G1 and a first-in-class CD38-targeting drug approved by the US Food and Drug Administration for the treatment of patients with relapsed/refractory and newly diagnosed multiple myeloma or newly diagnosed light-chain amyloidosis. CD38 is heavily expressed on malignant myeloma cells, and daratumumab exerts anti-myeloma activity via immune-mediated mechanisms, direct induction of apoptosis, and immunomodulation. Daratumumab is used as monotherapy or in combination with standard-of-care myeloma therapies, including proteasome inhibitors, immunomodulatory agents, DNA-alkylating agents, and corticosteroids. Following an intravenous infusion, daratumumab exhibits nonlinear pharmacokinetics (PK), as clearance decreases with higher doses and over time because of target-mediated effects. Dosing schedules vary depending on indications and co-administered drugs, but generally daratumumab is administered weekly for 6-9 weeks followed by a less frequent dosing regimen, once every 2-4 weeks. Daratumumab exposure is strongly correlated with efficacy, and the exposure-efficacy relationship follows a maximal effect model, whereas exposure is not correlated with safety endpoints. The approved dose of 16 mg/kg of daratumumab results in the saturation of 99% of the target at the end of weekly dosing in most patients, and high target saturation is maintained over time during the less frequent dosing schedule. Infusion-related reactions are frequently observed in patients given daratumumab, particularly with the first infusion, thus prompting long durations of infusion (~ 7 h) and splitting of the first dose across 2 days. This led to the development of a subcutaneous delivery formulation for daratumumab (Dara-SC). Dara-SC provides a similar efficacy and safety profile to intravenous daratumumab (Dara-IV) but has a much lower rate of infusion-related reactions and a shorter infusion time. Exposure-response relationships for efficacy and safety endpoints were similar between Dara-SC and Dara-IV, and co-administered drugs with either Dara-IV or Dara-SC do not significantly affect daratumumab PK. Except for baseline myeloma type and albumin level, none of the other investigated disease and patient characteristics (renal/hepatic function, age, sex, race, weight, Eastern Cooperative Oncology Group performance status) was identified to have clinically relevant effects on exposure to daratumumab monotherapy or combination therapy regimens. Dara-IV exposure was significantly lower in patients with immunoglobulin G myeloma compared with patients with non-immunoglobulin G myeloma (p < 0.0001) and in patients with a lower albumin level, whereas the overall response rate was similar regardless of the myeloma type and albumin level. Daratumumab dose adjustment is not currently recommended based on disease and patient characteristics.
引用
- Kim K, Phelps MA. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab. Clin Pharmacokinet. 2023. PMID: 37129750. doi:10.1007/s40262-023-01240-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。